C4 Therapeutics, Inc. — Director's Dealing 2020

Oct 2, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01

Reporting Person: COHEN ALAIN J (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series Seed Preferred Stock	$		Common Stock (237149)		Indirect
Series A Preferred Stock	$		Common Stock (1482183)		Indirect
Series B Preferred Stock	$		Common Stock (2484425)		Indirect
Stock Option (Right to Buy)	$2.11	2026-07-12	Common Stock (8561)		Direct

Footnotes

F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock is convertible into Common Stock on a 8.4335-to-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering ("IPO") without payment or further consideration. The shares have no expiration date.

F2: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent
of his pecuniary interest therein.

F3: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.

F4: 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such date.